M6A RNA Methylation-Mediated Dysregulation of AGAP2-AS1 Promotes Trastuzumab Resistance of Breast Cancer
Pharmacology · 2024
DOI: 10.1159/000539202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology, 2024. Verfasst von Yangjun Cai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid and Breast Surgery, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Breast Neoplasms, Trastuzumab, RNA, Long Noncoding. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Introduction
Trastuzumab is commonly used to treat human epidermal growth factor receptor-2-positive (HER2+) breast cancer, but its efficacy is often limited by chemotherapy resistance. Recent studies have indicated that long non-coding RNAs (lncRNAs) play important roles in tumor progression and response to therapy. However, the regulatory mechanisms associating lncRNAs and trastuzumab resistance remain unknown.
Methods
Quantitative polymerase chain reaction was performed to detect the expression of related genes. Western blot and immunofluorescence assays were used to evaluate protein expression levels. A series of gain- or loss-of-function assays confirmed the function of AGAP2-AS1 in trastuzumab resistance, both in vitro and in vivo. RNA immunoprecipitation and pull-down analyses were conducted to verify the interaction between METTL3/YTHDF2 and lncRNA AGAP2-AS1.
Results
AGAP2-AS1 was upregulated in trastuzumab-resistant cells and SKBR-3R-generated xenografts in nude mice. Silencing AGAP2-AS1 significantly decreased trastuzumab-induced cytotoxicity both in vitro and in vivo. Furthermore, m6A methylation of AGAP2-AS1 was reduced in trastuzumab-resistant cells compared to that in parental cells. In addition, METTL3 increased m6A methylation of AGAP2-AS1, which finally induced the suppressed AGAP2-AS1 expression. Moreover, YTHDF2 was essential for METTL3-mediated m6A methylation of AGAP2-AS1. Functionally, AGAP2-AS1 regulated trastuzumab resistance by inducing autophagy and increasing ATG5 expression. Conclusion: we demonstrated that METTL3/YTHDF2-mediated m6A methylation increased the expression of AGAP2-AS1, which could promote trastuzumab resistance in breast cancer. AGAP2-AS1 regulates trastuzumab resistance by inducing autophagy. Therefore, AGAP2-AS1 may be a promising predictive biomarker and therapeutic target in patients with breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thyroid and Breast Surgery, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China.
- Department of Pathology, Taizhou Hospital of Zhejiang Province, Linhai, China.
- Department of Oncology and Hematology, Taizhou Hospital of Zhejiang Province, Linhai, China.
- Department of Pharmacy, Taizhou Hospital of Zhejiang Province, Linhai, China.
Zitieren
APA
Cai, Y., Zheng, H., Xu, D., Xie, J., Wang, W., Liu, Z., & Zheng, Z. (2024). M6A RNA Methylation-Mediated Dysregulation of AGAP2-AS1 Promotes Trastuzumab Resistance of Breast Cancer. Pharmacology. https://doi.org/10.1159/000539202
Vancouver
Cai Y, Zheng H, Xu D, Xie J, Wang W, Liu Z, et al. M6A RNA Methylation-Mediated Dysregulation of AGAP2-AS1 Promotes Trastuzumab Resistance of Breast Cancer. Pharmacology. 2024. doi:10.1159/000539202
BibTeX
@article{Cai2024,
author = {Cai, Yangjun and Zheng, Haihong and Xu, Dong and Xie, Jingjing and Wang, Weiwen and Liu, Zhiwei and Zheng, Zhongqiu},
title = {M6A RNA Methylation-Mediated Dysregulation of AGAP2-AS1 Promotes Trastuzumab Resistance of Breast Cancer},
journal = {Pharmacology},
year = {2024},
doi = {10.1159/000539202}
}
EUVIMED